Sharemaestro company-news research for Akeso, Inc. (9926), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
HKG
Hong Kong
Measured evidence
Company news sentiment
9926 news sentiment
Akeso, Inc.
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone56Neutral is 50
Balanced news tone
53/100 evidence confidence
100% direct company focus
2 current stories across 1 publishers
Current company news
Price moving ahead of tone
Balanced news tone is drawn from 2 fresh independent stories, including 2 company-specific items across 1 publishers.
Latest source headline Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer finance.yahoo.com · 12 Aug 2026 13:22What supports the read
2 current stories are mapped specifically to 9926.
Cross-story agreement is 99/100, indicating a comparatively coherent tape.
What tempers the read
Only 1 publisher currently contribute to the measured read.
Price is moving more forcefully than the current news tone suggests.
56/100
Weighted toneBalanced news tone
53/100
Evidence confidencebuilding confidence
100%/100
Company focus2 direct stories
99/100
Evidence agreement1/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth23
1.83 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness78
recency-weighted evidenceAgreement99
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Price is moving more forcefully than the current news tone suggests.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
News subjects
What is shaping the score
Earnings641 stories · 50%
Market update621 stories · 50%
Source mix
Where the evidence comes from
finance.yahoo.com632 stories · 100%
Recurring subjects
Subjects appearing most often
Clinical Trials2Pharma1Oncology1Fourth Quarter1Fda Approval1Breast Cancer1Biotech1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#164Tone
finance.yahoo.comDirect company coverage
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Statistically Significant Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in NSCLC or Any Tumor Type MIAMI, August 12, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing
Clinical TrialsFda ApprovalFourth QuarterOncologyPharma
- Published
- 12 Aug 2026 13:22
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#262Tone
finance.yahoo.comDirect company coverage
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), in combination with ivonescimab (the Company's PD-1/VEGF bispecific antibody), for the treatment of advanced breast cancer. This study aims to explore the potential of Akeso's "IO2.0 + ADC2.0" regimen in advanced breast cancer, with a particular focus on first-line treatment of HR+/HER2- breast cancer an
BiotechBreast CancerClinical Trials
- Published
- 10 Aug 2026 04:05
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.